This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Karuna Therapeutics Stock (NASDAQ:KRTX) Get Karuna Therapeutics alerts:Sign Up Key Stats Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99VolumeN/AAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Read More Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRTX Stock News HeadlinesKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisAugust 12, 2025 | tipranks.comKaruna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 17, 2025 | tipranks.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 12 at 1:00 AM | Base Camp Trading (Ad)Karuna Therapeutics’ Phase 3 Study on KarXT: A Potential Game-Changer for Alzheimer’s PsychosisJuly 4, 2025 | tipranks.comKaruna Therapeutics Advances Alzheimer’s Psychosis Treatment with KarXT StudyJune 27, 2025 | tipranks.comThis FDA-approved drug promises a new way to treat schizophreniaSeptember 30, 2024 | msn.comBMS wins approval for schizophrenia drug acquired from KarunaSeptember 27, 2024 | msn.comBristol Myers to Purchase KarunaSeptember 13, 2024 | msn.comSee More Headlines KRTX Stock Analysis - Frequently Asked Questions How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($3.01) EPS for the quarter, missing the consensus estimate of ($2.65) by $0.36. The firm's revenue for the quarter was down 100.0% compared to the same quarter last year. When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Applied Materials (AMAT), Moderna (MRNA), Marvell Technology (MRVL) and Tesla (TSLA). Company Calendar Today11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KRTX CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year Founded2009Profitability EPS (Trailing Twelve Months)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$433.68 million Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654 thousand Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:KRTX) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | Sponsored55+? Elon’s Gift…James Altucher points to Elon Musk's latest FCC filing as a potential turning point for retirees relying on So...Paradigm Press | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. Af...Priority Gold | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karuna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
